The stars finally lined up today for me. I’m a/off work early, b/bored to DEATH of the LGBT news cycle (in which there’s nothing out there except who’s oppressing this week, and c/I’m LONG overdue for a roundup.
Even though I haven’t had the time to post daily for a while, I am watching the HIV/AIDS news cycle all the time. These are the bits that caught my eye and wanted to pass on. All content is from the respective linked articles, except where I might chime in (and that’ll be obvious..)
The AIDS Quilt will be on display this summer in it’s entirety for the first time this century. And they need volunteers bigtime.
The Food and Drug Administration moved the target date to Sept. 14 so it can review a plan by Gilead to ensure people wouldn’t misuse the drug, the Foster City, California-based company said yesterday in an e-mail. Gilead provided the agency a modified risk strategy on June 4, Cara Miller, a spokeswoman for the company, said in the e-mail.
Only one person ever has been cured of an HIV infection, and a presentation about the man at a scientific meeting in Sitges, Spain, last week has caused an uproar about the possibility that he’s still infected.
Timothy Brown, initially referred to as “the Berlin patient” until he went public about his cure, received unusual blood transplants 5 years ago to treat his leukemia. The blood came from a donor who had mutant cells resistant to HIV. Following the procedure, Brown stopped taking antiretrovirals (ARVs), the virus never returned, and his doctors reported that he had been cured.
The prevalence of high school students in the United States who were taught about HIV/AIDS decreased from 87 percent in 2009 to 84 percent in 2011, according to the 2011 National Youth Risk Behavior Survey from the Centers for Disease Control and Prevention.
Adherence to intermittent pre-exposure prophylaxis (PrEP) is significantly poorer than adherence to daily PrEP, according to a study published in PLoS One. The research involved men who have sex with men (MSM) and female sex workers in Kenya. Average adherence among the individuals taking daily treatment was 83%, but fell to just 55% for those taking